FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Avi Einzig

Research Profile

Chemicals & Drugs

Activities & Behaviors

Procedures

Disorders

Concepts & Ideas

Treatment Outcome

Co-author Network

Publications

TOP 3
Joseph A Sparano; Sandra Lee; Michael G Chen; Tipu Nazeer; Avi Einzig; Richard F Ambinder; David H Henry; Jane Manalo; Tianhong Li; Jamie H Von Roenn
Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).
N A Jan; Avi Einzig; Mark Suhrland; Peter H Wiernik
Non-Hodgkin lymphoma in acquired immunodeficiency syndrome manifesting as bilateral hypopyon.
Peter H Wiernik; Janice P Dutcher; Avi Einzig; Joseph A Sparano; M Frank; W Friedenberg
Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Avi Einzig (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2004: Joseph A Sparano; Sandra Lee; Michael G Chen; Tipu Nazeer; Avi Einzig; Richard F Ambinder; David H Henry; Jane Manalo; Tianhong Li; Jamie H Von Roenn
Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1491-500.
1999: N A Jan; Avi Einzig; Mark Suhrland; Peter H Wiernik
Non-Hodgkin lymphoma in acquired immunodeficiency syndrome manifesting as bilateral hypopyon.
American journal of clinical oncology 1999;22(1):82-3.
1998: Peter H Wiernik; Janice P Dutcher; Avi Einzig; Joseph A Sparano; M Frank; W Friedenberg
Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
The cancer journal from Scientific American 1998;4(4):254-60.
1997: Kevin P O'Boyle; Y Wang; Edward L Schwartz; DL Regl; Avi Einzig; Janice P Dutcher; Peter H Wiernik; Susan B. Horwitz
Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids.
Cancer 1997;79(5):1022-30.
1993: Joseph A Sparano; Scott Wadler; R B Diasio; R Zhang; Z Lu; Edward L Schwartz; Avi Einzig; Peter H Wiernik
Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1609-17.
1993: E T Walpole; Janice P Dutcher; Joseph A Sparano; Rasim Gucalp; Avi Einzig; Elisabeth Paietta; N Ciobanu; K Grima; G Caliendo; G Cavasotto
Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(4):275-81.
1993: C D Runowicz; Peter H Wiernik; Avi Einzig; Gary L Goldberg; Susan B. Horwitz
Taxol in ovarian cancer.
Cancer 1993;71(4 Suppl):1591-6.
1992: Avi Einzig; Peter H Wiernik; J Sasloff; C D Runowicz; Gary L Goldberg
Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1748-53.
1991: Avi Einzig; H Hochster; Peter H Wiernik; D L Trump; Janice P Dutcher; E Garowski; J Sasloff; T J Smith
A phase II study of taxol in patients with malignant melanoma.
Investigational new drugs 1991;9(1):59-64.
1991: Avi Einzig; P H Wiernik; Edward L Schwartz
Taxol: a new agent active in melanoma and ovarian cancer.
Cancer treatment and research 1991;58():89-100.
1991: Avi Einzig; E Gorowski; J Sasloff; Peter H Wiernik
Phase II trial of taxol in patients with metastatic renal cell carcinoma.
Cancer investigation 1991;9(2):133-6.
1988: Scott Wadler; Avi Einzig; Janice P Dutcher; N Ciobanu; L Landau; Peter H Wiernik
Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma.
American journal of clinical oncology 1988;11(1):55-9.
1987: Peter H Wiernik; Edward L Schwartz; Avi Einzig; J J Strauman; richard lipton; Janice P Dutcher
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(8):1232-9.